Back to Search Start Over

CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung tumors

Authors :
Karaki, Soumaya
Blanc, Charlotte
Tran, Thi
Galy-Fauroux, Isabelle
Mougel, Alice
Dransart, Estelle
Anson, Marie
Tanchot, Corinne
Paolini, Lea
Gruel, Nadege
Gibault, Laure
Lepimpec-Barhes, Francoise
Fabre, Elizabeth
Benhamouda, Nadine
Badoual, Cecile
Damotte, Diane
Donnadieu, Emmanuel
Kobold, Sebastian
Mami-Chouaib, Fathia
Golub, Rachel
Johannes, Ludger
Tartour, Eric
Vougny, Marie-Christine
Université Sorbonne Paris Cité - - USPC2011 - ANR-11-IDEX-0005 - IDEX - VALID
Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970))
Hôpital Européen Georges Pompidou [APHP] (HEGP)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
Equipe labellisée Ligue contre le Cancer
Chimie biologique des membranes et ciblage thérapeutique (CBMCT - UMR 3666 / U1143)
Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)
Unité de génétique et biologie des cancers (U830)
Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
Département de Recherche Translationnelle
Institut Curie [Paris]
Service d’anatomo‑pathologie [AP-HP Hôpital Européen Georges Pompidou] (Centre de Ressources biologiques)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138))
École pratique des hautes études (EPHE)
Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
Hôpital Cochin [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Institut Cochin (IC UM3 (UMR 8104 / U1016))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
Center for Integrated Protein Science (CIPSM)
Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Ludwig-Maximilians-Universität München (LMU)-Helmholtz Zentrum München = German Research Center for Environmental Health
German Center for Lung Research - DZL [Munich, Germany]
Immunologie intégrative des tumeurs et immunothérapie des cancers (INTIM)
Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
Lymphopoïèse (Lymphopoïèse (UMR_1223 / U1223 / U-Pasteur_4))
Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
This work has been funded by Fondation ARC, INCA PLBio, Labex Immuno-Oncology, Site intégré de recherche en cancérologie (SIRIC CARPEM, SIRIC Curie), Cancéropole d’Ile de France, Carnot Curie Cancer, FONCER. SK is supported by the European Research Council (grant 756017, ARMOR-T).
ANR-11-IDEX-0005,USPC,Université Sorbonne Paris Cité(2011)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
Centre National de la Recherche Scientifique (CNRS)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)
Département de recherche translationnelle
Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)
Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Helmholtz-Zentrum München (HZM)-Ludwig Maximilian University of Munich [Germany] (LMU München)
Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
École Pratique des Hautes Études (EPHE)
Technical University of Munich (TUM)-Ludwig Maximilian University of Munich [Germany] (LMU München)-Helmholtz-Zentrum München (HZM)
Source :
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021), Journal for Immunotherapy of Cancer, Journal for Immunotherapy of Cancer, 2021, 9 (3), pp.e001948. ⟨10.1136/jitc-2020-001948⟩, Journal for Immunotherapy of Cancer, BMJ Publishing Group 2021, 9 (3), pp.e001948. ⟨10.1136/jitc-2020-001948⟩
Publication Year :
2021
Publisher :
BMJ Publishing Group, 2021.

Abstract

International audience; Background Resident memory T lymphocytes (TRM) are located in tissues and play an important role in immunosurveillance against tumors. The presence of TRM prior to treatment or their induction is associated to the response to anti-Programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) immunotherapy and the efficacy of cancer vaccines. Previous work by our group and others has shown that the intranasal route of vaccination allows more efficient induction of these cells in head and neck and lung mucosa, resulting in better tumor protection. The mechanisms of in vivo migration of these cells remains largely unknown, apart from the fact that they express the chemokine receptor CXCR6.Methods We used CXCR6-deficient mice and an intranasal tumor vaccination model targeting the Human Papillomavirus (HPV) E7 protein expressed by the TC-1 lung cancer epithelial cell line. The role of CXCR6 and its ligand, CXCL16, was analyzed using multiparametric cytometric techniques and Luminex assays.Human biopsies obtained from patients with lung cancer were also included in this study.Results We showed that CXCR6 was preferentially expressed by CD8+ TRM after vaccination in mice and also on intratumoral CD8+ TRM derived from human lung cancer. We also demonstrate that vaccination of Cxcr6-deficient mice induces a defect in the lung recruitment of antigen-specific CD8+ T cells, preferentially in the TRM subsets. In addition, we found that intranasal vaccination with a cancer vaccine is less effective in these Cxcr6-deficient mice compared with wild-type mice, and this loss of efficacy is associated with decreased recruitment of local antitumor CD8+ TRM. Interestingly, intranasal, but not intramuscular vaccination induced higher and more sustained concentrations of CXCL16, compared with other chemokines, in the bronchoalveolar lavage fluid and pulmonary parenchyma.Conclusions This work demonstrates the in vivo role of CXCR6-CXCL16 axis in the migration of CD8+ resident memory T cells in lung mucosa after vaccination, resulting in the control of tumor growth. This work reinforces and explains why the intranasal route of vaccination is the most appropriate strategy for inducing these cells in the head and neck and pulmonary mucosa, which remains a major objective to overcome resistance to anti-PD-1/PD-L1, especially in cold tumors.

Details

Language :
English
ISSN :
20511426
Volume :
9
Issue :
3
Database :
OpenAIRE
Journal :
Journal for ImmunoTherapy of Cancer
Accession number :
edsair.pmid.dedup....ba01d6432ebe282696d961c35b5e4c96